APA (7th ed.) Citation

Patnaik, A., LoRusso, P. M., Messersmith, W. A., Papadopoulos, K. P., Gore, L., Beeram, M., . . . Weekes, C. D. (2014). A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 73(5), 951-960. https://doi.org/10.1007/s00280-014-2426-8

Chicago Style (17th ed.) Citation

Patnaik, Amita, et al. "A Phase Ib Study Evaluating MNRP1685A, a Fully Human Anti-NRP1 Monoclonal Antibody, in Combination with Bevacizumab and Paclitaxel in Patients with Advanced Solid Tumors." Cancer Chemotherapy and Pharmacology 73, no. 5 (2014): 951-960. https://doi.org/10.1007/s00280-014-2426-8.

MLA (9th ed.) Citation

Patnaik, Amita, et al. "A Phase Ib Study Evaluating MNRP1685A, a Fully Human Anti-NRP1 Monoclonal Antibody, in Combination with Bevacizumab and Paclitaxel in Patients with Advanced Solid Tumors." Cancer Chemotherapy and Pharmacology, vol. 73, no. 5, 2014, pp. 951-960, https://doi.org/10.1007/s00280-014-2426-8.